The endothelin axis: Emerging role in cancer

Nature Reviews Cancer

Volumn 3, Issue 2, 2003, Pages 110-116

  Nelson, Joel ^a   Bagnato, Anna ^b   Battistini, Bruno ^c   Nisen, Perry ^d  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^c LAVAL UNIVERSITY   (Canada)

^d ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 BUTYL 7 [2 (2 CARBOXYPROPYL) 4 METHOXYPHENYL] 5 (3,4 METHYLENEDIOXYPHENYL)CYCLOPENTENO[1,2 B]PYRIDINE 6 CARBOXYLIC ACID; 27 O [3 [2 (3 CARBOXYACRYLOYLAMINO) 5 HYDROXYPHENYL]ACRYLOYLOXY]MYRICERONE; ATRASENTAN; BOSENTAN; ENDOTHELIN; ENDOTHELIN 1; ENDOTHELIN 2; ENDOTHELIN 3; ENDOTHELIN A RECEPTOR; ENDOTHELIN A RECEPTOR ANTAGONIST; ENDOTHELIN B RECEPTOR; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; FAS LIGAND; FIBROBLAST GROWTH FACTOR 1; FIBROBLAST GROWTH FACTOR 2; MATRIX METALLOPROTEINASE; MITOGEN ACTIVATED PROTEIN KINASE; MYC PROTEIN; N (2,6 DIMETHYLPIPERIDINOCARBONYL) 4 METHYLLEUCYL DEXTRO (1 METHOXYCARBONYLTRYPTOPHANYL) DEXTRO NORLEUCINE; PROTEIN BCL 2; PROTEIN C FOS; PROTEIN C JUN; PROTEIN KINASE C; RAF PROTEIN; RAS PROTEIN; SOMATOMEDIN C; UNINDEXED DRUG; UROKINASE; VASCULOTROPIN; ANTINEOPLASTIC AGENT; ENDOTHELIN RECEPTOR; PYRROLIDINE DERIVATIVE;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; CANCER INHIBITION; CANCER RESEARCH; CARCINOGENESIS; CELL DIFFERENTIATION; CELL PROLIFERATION; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; HORMONE SYNTHESIS; HUMAN; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROSTATE CANCER; PULMONARY HYPERTENSION; REVIEW; SIGNAL TRANSDUCTION; TUMOR VASCULARIZATION; AMINO ACID SEQUENCE; CHEMISTRY; DRUG ANTAGONISM; MALE; NEOPLASM; PATHOPHYSIOLOGY; PHYSIOLOGY; PROSTATE TUMOR; PROTEIN CONFORMATION;

AMINO ACID SEQUENCE; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; ENDOTHELINS; HUMANS; MALE; NEOPLASMS; PROSTATIC NEOPLASMS; PROTEIN CONFORMATION; PYRROLIDINES; RECEPTOR, ENDOTHELIN A; RECEPTORS, ENDOTHELIN;

EID: 0037317520     PISSN: 1474175X     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrc990     Document Type: Review

References (73)

1. Levin, E. R Endothelins. N. Engl. J. Med. 333, 356-363 (1995).
2. Goldie, R. G. Endothelins in health and disease: an overview. Clin. Exp. Pharmacol. Physiol. 26, 145-148 (1999).
3. Walden, P. D., Ittmann, M., Monaco, M. E. & Lepor, H. Endothelin-1 production and agonist activities in cultured prostate-derived cells: implications for regulation of endothelin bioactivity and bioavailability in prostatic hyperplasia. Prostate 34, 241-250 (1998).
4. Masaki, T. The endothelin family: an overview. J. Cardiovasc. Pharmacol. 35, S3-S5 (2000).
5. Valdenaire, O., Rohrbacher, E. & Mattei, M. G. Organization of the gene encoding the human endothelin-converting enzyme (ECE-1). J. Biol. Chem. 270, 29794-29798 (1995).
6. Bagnato, A. & Catt, K. J. Endothelin as autocrine regulators of tumor cell growth. Trends Endocr. Metab. 9, 378-383 (1998).
7. Bloch, K. D. et al. Structural organization and chromosomal assignment of the gene encoding endothelin. J. Biol. Chem. 264, 10851-10857 (1989).
8. Battistini, B., Chailler P., D'Odeans-Juste, P., Briere, N. & Sirois, P. Growth regulatory properties of endothelins. Peptides 14, 385-399 (1993).
9. Nelson, J. B. & Carducci, M. A. The role of the endothelin axis in prostate cancer. Prostate J. 1, 126-130 (1999).
10. Remuzzi, G., Perico, N. & Benigni, A. New therapeutics that antagonize endothelin: promises and frustrations. Nature Rev. Drug Disc. 1, 986-1000 (2002).
11. Pristivishalil, G. & Nelson, J. B. Endothelium-derived factors as paracrine mediators of prostate cancer progression. Prostate 44, 44-77 (2000).
12. Opgenorth, T. J. Endothelin receptor antagonism. Adv. Pharmacol. 33, 1-65 (1995).
13. Lusher, T. F. & Barton, M. Endothelins and endothelin receptor antagonists: therapeutic considerations for a novel class of cardiovascular drugs. Circulation 102, 2434-2440 (2000).
14. Clozel. M. Endothelin receptor antagonists: current status and perspectives. J. Cardiovasc. Pharmacol. 35 (Suppl. 2), S65-S68 (2000).
15. Today in Cardiology news source. Cardiovascular Drugs in the Pipeline [online], (cited 1 Dec 2002), 〈 www.todayincardiology.com/200301/pipeline.pdf〉 (2003).
16. Nelson, J. B. et al. Endothelin-1 production and decreased endothelin B receptor expression in advanced prostate cancer. Cancer Res. 56, 663-668 (1996).
17. Daub, H. et al. Role of transactivation of the EGF receptor in signaling by G-protein-coupled receptors. Nature 379, 557-560 (1996).
18. Vacca, F., Bagnato, A., Catt, K. J. & Tecce, R. Transactivation of the epidermal growth factor receptor in endothelin-1-induced mitogenic signaling in human ovarian carcinoma cells. Cancer Res. 60, 5310-5317 (2000).
19. Filippatos, G. S. et al. Regulation of apoptosis by vasoactive peptides. Am. J. Physiol. Lung Cell. Mol. Physiol. 281, L749-L761 (2001).
20. Wu-Wong, J. R., Chiou, W. J. Dickinson, R. & Opgenorth, T. J. Endothelin attenuates apoptosis in human smooth muscle cells. Biochem. J. 328, 733-737 (1997).
21. Wu-Wong, J. R., Chiou, W. J. & Wang, J. Extracellular signal-regulated kinases are involved in the antiapoptotic effect of endothelin-1. J. Pharmacol. Exp. Ther. 293, 514-521 (2000).
22. Shichin, M., Kato, H., Marumo, F. & Hirata, Y. Endothelin-1 as an autecrine/paracrine apoptosis survival factor for endothelial cells. Hypertension 30, 1198-1203 (1997).
23. Eberl, L. P., Egidy, G., Pinet, F. & Juillerat-Jeanneret, L. Endothelin receptor blockade potentiates FasL-induced apoptosis in colon carcinoma cells via the protein kinase C-pathway. J. Cardiovasc. Pharmacol. 36, S354-S356 (2000).
24. B-receptor antagonism did not control tumour progression.
25. A-receptor antagonism in the osteoblastic response.
26. Boyce, B. F., Yoneda, T. & Guise, T. A. Factors regulating the growth of metastatic cancer in bone. Endocrine-Related Cancer 6, 333-347 (1999).
27. Mundy, G. R. Metastasis to bone: causes, consequences and therapeutic opportunities. Nature Rev. Cancer 2, 584-593 (2002).
28. Guise, T. A. Molecular mechanisms of osteolytic bone metastases. Cancer 88 (Suppl.), 2892-2898 (2000).
29. Chiao, J. W. et al. Endothelin-1 from prostate cancer cells is enhanced by bone contact which blocks osteoclastic bone resorption. Br. J. Cancer 83, 360-365 (2000).
30. Salani, D. et al. Role of endothelin-1 in neovascularization of ovarian carcinoma. Am. J. Pathol. 157, 1537-1547 (2000).
31. Bek, E. L. & McMillen, M. A. Endothelins are angiogenic. J. Cardiovasc. Pharmacol. 36, S135-S139 (2000).
32. Bagnato, A. et al. Expression of endothelin 1 and endothelin A receptor in ovarian carcinoma: evidence for an autocrine role in tumor growth. Cancer Res. 59, 720-727 (1999).
33. Salani, D. et al. Endothelin-1 induces an angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo. Am. J. Pathol. 157, 1703-1171 (2000).
34. Spinella, F., Rosano, L., Di Castro, V., Natali, P. G. & Bagnato, A. Endothelin-1 induces vascular endothelial growth factor by increasing hypoxia-inducible factor 1α in ovarian cancer cells J. Biol. Chem. 277, 27850-27855 (2002).
35. Rosano, L. et al. Endothelin-1 induces tumor proteinase activation and invasiveness of ovarian carcinoma cells. Cancer Res. 61, 8340-8346 (2001).
36. Rosano, L. et al. Endothelin-1 promotes proteolytic activity of ovarian carcinoma. Clin. Sci. 103, 306S-309S (2002).
37. Nelson, J. B. et al. Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nature Med. 1, 944-949 (1995). First description of ET-1 as a potentially important factor in advanced prostate cancer progression, leading to the idea that targeting the endothelin axis might be therapeutic.
38. Nelson, J. B. et al. Methylation of the 5′ CpG island of the endothelin B receptor gene is common in human prostate cancer. Cancer Res. 57, 35-37 (1997).
39. Gohji, K et al. Expression of endothelin receptor A associated with prostate cancer progression. J. Urol. 165, 1033-1036 (2001).
40. Nelson, J. B. et al. The endothelin receptor antagonist atrasentan improves the time to clinical progression in hormone refractory prostate cancer patients: a randomized, double-blind, multi-national study. J. Urol. 16, 168 (2001).
41. Nelson, J. B. et al. Preliminary phase II results using ABT-627, an endothelin-A selective receptor antagonist, in men with symptomatic hormone refractory prostate cancer. J. Urol 163, 159 (2000).
42. van der Boon, J. New drug slows prostate-cancer progression. Lancet Oncol. 3, 201 (2002).
43. Carducci, M. A. et al. Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, Phase II, placebo-controlled trial. J. Clin. Oncol. (in the press).
44. Bagnato, A. et al. Autocrine actions of endothelin-1 as a growth factor in human ovarian carcinoma cells. Clin. Cancer Res. 1, 1059-1066 (1995). First description of ET-1 production by ovarian carcinoma; ET-1-induced proliferation of ovarian cancer is mediated by the ETA receptor.
45. Moraitis, S., Langdon, S. P. & Miller, W. R. Endothelin expression and responsiveness in human ovarian carcinoma cell lines. Eur. J. Cancer 33, 661-668 (1997).
46. Moraitis, S., Miller, W. R., Smyth, J. F. & Langdon, S. P. Paracnne regulation of ovarian cancer by endothelin. Eur. J. Cancer 35, 1381-1387 (1999).
47. Del Bufalo, D. et al. Endothelin-1 protects ovarian carcinoma cells against paclitaxel-induced apoptosis: requirement for Akt activation. Mol. Pharmacol. 61, 524-532 (2002).
48. Giaid, A. et al. Detection of endothelin immunoreactivity and mRNA in pulmonary tumours. J. Pathol. 162, 15-22 (1990).
49. Ahmed, S. I., Thompson, J., Coulson, J. M. & Woll, P. J. Studies on the expression of endothelin, its receptor subtypes, and converting enzymes in lung cancer and in human bronchial epithelium. Am. J. Respir. Cell. Mol. Biol. 22, 422-491 (2000).
50. Zhao, Y. D. et al. Localization and characterization of endothelin-1 receptor binding in the blood vessels of human pulmonary tumors. J. Cardiovaso. Res. 26, S341-S345 (1995).
51. Egidy, G. et al. Modulation of human colon tumor-stromal interactions by the endothelin system. Am. J. Pathol. 157, 1863-1874 (2000).
52. A receptor antagonism. Br. J. Cancer 85, 1759-1763 (2001).
53. Thevarajah, S., Udan, M. S., Zheng, H., Pfluyg, B. R. & Nelson, J. B. Endothelin axis expression in renal cell carcinoma. J. Urol. 161, 137 (1999).
54. Venuti, A., Salani, D., Manni, V., Poggiali, F. & Bagnato, A. Expression of endothelin 1 and endothelin A receptor in HPV-associated cervical carcinoma: new potential targets for anticancer therapy. FASEB J. 14, 2277-2283 (2000).
55. Bagnato, A. et al. Growth inhibition of cervix carcinoma cells in vivo by endothelin A receptor blockade. Cancer Res. 62, 6381-6384 (2002). Complete inhibition of cervical carcinoma growth in vivo with atrasentan treatment alone; antitumour effects were additive in combination with the chemotherapeutic agent paclitaxel.
56. Pagotto, U. et al. Expression and localization of endothelin-1 and endothelin receptors in human meningiomas. Evidence for a role in tumoral growth. J. Clin. Invest. 96, 2017-2025 (1995).
57. B) in brain tumors and normal human brain. J. Cardiovasc. Pharmacol. 26, S104-S106 (1995).
58. A receptors in human gliomas and meningiomas, with high affinity for the selective antagonist PD156707. Neurosurgery 43, 890-898 (1998).
59. Papandreou, C. N. et al. Neutral endopeptidase 24.11 loss in metastatic human prostate cancer contributes to androgen-independent progression. Nature Med. 4, 50-57 (1998). First description of the loss of expression and activity of NEP - the enzyme responsible for ET-1 degradation - in advanced prostate cancer.
60. A blockade with atrasentan for cancer treatment.
61. Salani, D. et al. ABT-627, a potent endothelin receptor A antagonist, inhibits ovarian carcinoma growth in vitro. Clin. Sci. 103, 318S-321S (2002).
62. Yamashita, J. et al. A large amount of endothelin-1 is present in human breast cancer tissues. Res. Commun. Chem. Pathol. Pharmacol. 74, 363-369 (1991).
63. Alanen, K., Deng, D. X. & Chakrabarti, S. Augmented expression of endothelin-1, endothelin-3 and the endothelin-B receptor in breast carcinoma. Histopathology 36, 161-167 (2000).
64. Grimshaw, M. J., Naylor, S. & Balkwill, F. R. Endothelin-2 is a hypoxia-induced autocrine survival factor for breast tumor cells. Mol. Cancer Ther. 14, 1273-1281 (2002).
65. Bagnato, A. et al. Endothelin receptor blockade inhbits proliferation of Kaposi's sarcoma cells. Am. J. Pathol. 158, 841-847 (2001).
66. B receptor seems to be central in melanoma.
67. Krum, H. The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension, N. Engl. J. Med. 338, 784-790 (1998).
68. Yohn, J. J. et al. Human melanoma cells express functional endothelin-1 receptors. Biochem. Biophys. Res. Commun. 201, 449-457 (1994).
69. Kikuchi, K. et al. Decreased ET(B) receptor expression in human metastatic melanoma cells. Biochem. Biophys. Res. Commun. 219, 734-739 (1996).
70. Eberle, J. et al. Downregulation of endothelin B receptor in human melanoma cell lines parallel to differentiation genes. J. Invest. Dermatol. 112, 925-932 (1999).
71. Demunter, A., De Wolf-Peeters, C., Degreef, H., Stas, M. & van den Oord, J. J. Expression of the endothelin-B receptor in pigment cell lesions of the skin. Evidence for its role as tumor progression marker in malignant melanoma. Virchows Arch. 438, 485-491 (2001).
72. 3. Mol. Pharmacol. 47, 266-271 (1995).
73. 125I-ET-1) binding to human meningiomas and antagonizes ET-1-induced proliferation of meningioma cells. Cell. Mol. Neurobiol. 14, 105-118 (1994).